ICN pharmaceuticals: corporate governance analysis

ICN Pharmaceuticals, Inc. (today Valeant Pharmaceuticals International) was a drug developer and manufacturer, known in the medical field for its development of Ribavirin, an antiviral compound used to treat various viral infections. However, ICN will probably be remembered mostly as an example of p...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Corporate Ownership and Control 2010, Vol.7 (4), p.73-89
Hauptverfasser: Grove, Hugh, Čupić, Milan
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 89
container_issue 4
container_start_page 73
container_title Corporate Ownership and Control
container_volume 7
creator Grove, Hugh
Čupić, Milan
description ICN Pharmaceuticals, Inc. (today Valeant Pharmaceuticals International) was a drug developer and manufacturer, known in the medical field for its development of Ribavirin, an antiviral compound used to treat various viral infections. However, ICN will probably be remembered mostly as an example of problematic and inefficient corporate governance. Changes in the management structure of ICN occurred almost at the same time when corporations, like Enron, WorldCom, Tyco, were dealing with financial scandals caused by problems in corporate governance. Since ICN was not a powerful corporation and found a way to deal with its problems, it was not subject of any big financial scandal. Nevertheless, it is interesting how ICN managed to operate, in some years even successfully, with so many corporate governance problems and how Milan Panic managed to stay at the top of ICN for 42 years, in spite of his numerous expensive law suits, scandals and bad decisions.
doi_str_mv 10.22495/cocv7i4p6
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_850557662</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>850557662</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2366-5536c8c9061b07992bc1631bd3b28c0c59fa3ba5a04d847c5f682ec20ba6c5c13</originalsourceid><addsrcrecordid>eNo9kM1Kw0AURgdRsNRufILsBCE6_zNxJ0VroehG18Od24kGkkycSQp9e4MVV9-3OJzFIeSa0TvOZaXuMeLBNHLQZ2TBLKOloMqcz99wU1Zc8EuyyrnxVEojhGFsQfh2_VoMX5A6wDCNDUKbHwqMaYgJxlB8xkNIPfQYCuihPeYmX5GLeqbC6m-X5OP56X39Uu7eNtv1465ELrQulRIaLVZUM09NVXGPTAvm98JzixRVVYPwoIDKvZUGVa0tD8ipB40KmViSm5N3SPF7Cnl0XZMxtC30IU7ZWUWVMlrzmbw9kZhizinUbkhNB-noGHW_adx_GvEDATpW-Q</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>850557662</pqid></control><display><type>article</type><title>ICN pharmaceuticals: corporate governance analysis</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Grove, Hugh ; Čupić, Milan</creator><creatorcontrib>Grove, Hugh ; Čupić, Milan</creatorcontrib><description>ICN Pharmaceuticals, Inc. (today Valeant Pharmaceuticals International) was a drug developer and manufacturer, known in the medical field for its development of Ribavirin, an antiviral compound used to treat various viral infections. However, ICN will probably be remembered mostly as an example of problematic and inefficient corporate governance. Changes in the management structure of ICN occurred almost at the same time when corporations, like Enron, WorldCom, Tyco, were dealing with financial scandals caused by problems in corporate governance. Since ICN was not a powerful corporation and found a way to deal with its problems, it was not subject of any big financial scandal. Nevertheless, it is interesting how ICN managed to operate, in some years even successfully, with so many corporate governance problems and how Milan Panic managed to stay at the top of ICN for 42 years, in spite of his numerous expensive law suits, scandals and bad decisions.</description><identifier>ISSN: 1727-9232</identifier><identifier>EISSN: 1810-3057</identifier><identifier>DOI: 10.22495/cocv7i4p6</identifier><language>eng</language><subject>Corporate governance ; Decision making ; Finance ; Financial reporting ; Legislation ; Litigation ; Pharmaceutical industry ; Senior management ; U.S.A</subject><ispartof>Corporate Ownership and Control, 2010, Vol.7 (4), p.73-89</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2366-5536c8c9061b07992bc1631bd3b28c0c59fa3ba5a04d847c5f682ec20ba6c5c13</cites><orcidid>0000-0002-0150-6682 ; 0000-0002-0884-7682</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids></links><search><creatorcontrib>Grove, Hugh</creatorcontrib><creatorcontrib>Čupić, Milan</creatorcontrib><title>ICN pharmaceuticals: corporate governance analysis</title><title>Corporate Ownership and Control</title><description>ICN Pharmaceuticals, Inc. (today Valeant Pharmaceuticals International) was a drug developer and manufacturer, known in the medical field for its development of Ribavirin, an antiviral compound used to treat various viral infections. However, ICN will probably be remembered mostly as an example of problematic and inefficient corporate governance. Changes in the management structure of ICN occurred almost at the same time when corporations, like Enron, WorldCom, Tyco, were dealing with financial scandals caused by problems in corporate governance. Since ICN was not a powerful corporation and found a way to deal with its problems, it was not subject of any big financial scandal. Nevertheless, it is interesting how ICN managed to operate, in some years even successfully, with so many corporate governance problems and how Milan Panic managed to stay at the top of ICN for 42 years, in spite of his numerous expensive law suits, scandals and bad decisions.</description><subject>Corporate governance</subject><subject>Decision making</subject><subject>Finance</subject><subject>Financial reporting</subject><subject>Legislation</subject><subject>Litigation</subject><subject>Pharmaceutical industry</subject><subject>Senior management</subject><subject>U.S.A</subject><issn>1727-9232</issn><issn>1810-3057</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><recordid>eNo9kM1Kw0AURgdRsNRufILsBCE6_zNxJ0VroehG18Od24kGkkycSQp9e4MVV9-3OJzFIeSa0TvOZaXuMeLBNHLQZ2TBLKOloMqcz99wU1Zc8EuyyrnxVEojhGFsQfh2_VoMX5A6wDCNDUKbHwqMaYgJxlB8xkNIPfQYCuihPeYmX5GLeqbC6m-X5OP56X39Uu7eNtv1465ELrQulRIaLVZUM09NVXGPTAvm98JzixRVVYPwoIDKvZUGVa0tD8ipB40KmViSm5N3SPF7Cnl0XZMxtC30IU7ZWUWVMlrzmbw9kZhizinUbkhNB-noGHW_adx_GvEDATpW-Q</recordid><startdate>2010</startdate><enddate>2010</enddate><creator>Grove, Hugh</creator><creator>Čupić, Milan</creator><scope>AAYXX</scope><scope>CITATION</scope><scope>8BJ</scope><scope>FQK</scope><scope>JBE</scope><orcidid>https://orcid.org/0000-0002-0150-6682</orcidid><orcidid>https://orcid.org/0000-0002-0884-7682</orcidid></search><sort><creationdate>2010</creationdate><title>ICN pharmaceuticals: corporate governance analysis</title><author>Grove, Hugh ; Čupić, Milan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2366-5536c8c9061b07992bc1631bd3b28c0c59fa3ba5a04d847c5f682ec20ba6c5c13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Corporate governance</topic><topic>Decision making</topic><topic>Finance</topic><topic>Financial reporting</topic><topic>Legislation</topic><topic>Litigation</topic><topic>Pharmaceutical industry</topic><topic>Senior management</topic><topic>U.S.A</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Grove, Hugh</creatorcontrib><creatorcontrib>Čupić, Milan</creatorcontrib><collection>CrossRef</collection><collection>International Bibliography of the Social Sciences (IBSS)</collection><collection>International Bibliography of the Social Sciences</collection><collection>International Bibliography of the Social Sciences</collection><jtitle>Corporate Ownership and Control</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Grove, Hugh</au><au>Čupić, Milan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ICN pharmaceuticals: corporate governance analysis</atitle><jtitle>Corporate Ownership and Control</jtitle><date>2010</date><risdate>2010</risdate><volume>7</volume><issue>4</issue><spage>73</spage><epage>89</epage><pages>73-89</pages><issn>1727-9232</issn><eissn>1810-3057</eissn><abstract>ICN Pharmaceuticals, Inc. (today Valeant Pharmaceuticals International) was a drug developer and manufacturer, known in the medical field for its development of Ribavirin, an antiviral compound used to treat various viral infections. However, ICN will probably be remembered mostly as an example of problematic and inefficient corporate governance. Changes in the management structure of ICN occurred almost at the same time when corporations, like Enron, WorldCom, Tyco, were dealing with financial scandals caused by problems in corporate governance. Since ICN was not a powerful corporation and found a way to deal with its problems, it was not subject of any big financial scandal. Nevertheless, it is interesting how ICN managed to operate, in some years even successfully, with so many corporate governance problems and how Milan Panic managed to stay at the top of ICN for 42 years, in spite of his numerous expensive law suits, scandals and bad decisions.</abstract><doi>10.22495/cocv7i4p6</doi><tpages>17</tpages><orcidid>https://orcid.org/0000-0002-0150-6682</orcidid><orcidid>https://orcid.org/0000-0002-0884-7682</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1727-9232
ispartof Corporate Ownership and Control, 2010, Vol.7 (4), p.73-89
issn 1727-9232
1810-3057
language eng
recordid cdi_proquest_miscellaneous_850557662
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Corporate governance
Decision making
Finance
Financial reporting
Legislation
Litigation
Pharmaceutical industry
Senior management
U.S.A
title ICN pharmaceuticals: corporate governance analysis
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T23%3A25%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ICN%20pharmaceuticals:%20corporate%20governance%20analysis&rft.jtitle=Corporate%20Ownership%20and%20Control&rft.au=Grove,%20Hugh&rft.date=2010&rft.volume=7&rft.issue=4&rft.spage=73&rft.epage=89&rft.pages=73-89&rft.issn=1727-9232&rft.eissn=1810-3057&rft_id=info:doi/10.22495/cocv7i4p6&rft_dat=%3Cproquest_cross%3E850557662%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=850557662&rft_id=info:pmid/&rfr_iscdi=true